Stoke Therapeutics Inc Total Liabilities
Stoke Therapeutics Inc total liabilities. Based on the latest financial reports, Stoke Therapeutics Inc (STOK) has total liabilities worth $48.42 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Stoke Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Stoke Therapeutics Inc (2017–2025)
Total liabilities of Stoke Therapeutics Inc from 2017 to 2025. This chart illustrates how Stoke Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Stoke Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Stoke Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Stoke Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Emami Limited
NSE:EMAMILTD
|
India | Rs9.14 Billion |
|
Wafer Works
TWO:6182
|
Taiwan | NT$10.61 Billion |
|
CHINA CONCH VENT. HD -01
F:68C
|
Germany | €33.41 Billion |
|
Douglas Emmett Inc
NYSE:DEI
|
USA | $6.04 Billion |
|
FirstSun Capital Bancorp Common Stock
NASDAQ:FSUN
|
USA | $13.88 Billion |
|
Alembic Pharmaceuticals Limited
NSE:APLLTD
|
India | Rs30.81 Billion |
|
Suzhou Secote Precision Electronic Co Ltd Class A
SHG:603283
|
China | CN¥2.74 Billion |
|
Beijing Jiuzhou Yi Gui Environmental Technology Co. Ltd.
SHG:688485
|
China | CN¥518.26 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Stoke Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Stoke Therapeutics Inc.
Liquidity & Leverage Metrics
Stoke Therapeutics Inc Total Liabilities Ratios Explained
Stoke Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Stoke Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Stoke Therapeutics Inc (2017–2025)
The table below shows the annual total liabilities of Stoke Therapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $65.98 Million | +55.12% |
| 2024-12-31 | $42.53 Million | -38.16% |
| 2023-12-31 | $68.78 Million | -3.43% |
| 2022-12-31 | $71.22 Million | +237.72% |
| 2021-12-31 | $21.09 Million | +78.00% |
| 2020-12-31 | $11.85 Million | +174.11% |
| 2019-12-31 | $4.32 Million | +74.91% |
| 2018-12-31 | $2.47 Million | -33.77% |
| 2017-12-31 | $3.73 Million | -- |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials fo… Read more